Functional Connectome Predicting Individual Gait Function and Its Relationship with Molecular Architecture in Parkinson's Disease

Haoting Wu,Chenqing Wu,Jianmei Qin,Cheng Zhou,Sijia Tan,Xiaojie DuanMu,Xiaojun Guana,Xueqin Bai,Tao Guo,Jingjing Wu,Jingwen Chen,Jiaqi Wen,Zhengye Cao,Ting Gao,Luyan Gu,Peiyu Huang,Baorong Zhang,Xiaojun Xu,Minming Zhang

DOI: https://doi.org/10.1016/j.nbd.2023.106216

IF: 7.046

2023-01-01

Neurobiology of Disease

Abstract:Gait impairment is a common symptom of Parkinson's disease (PD), but its neural signature remains unclear due to the interindividual variability of gait performance. Identifying a robust gait-brain correlation at the individual level would provide insight into a generalizable neural basis of gait impairment. In this context, this study aimed to detect connectome that can predict individual gait function of PD, and follow-up analyses assess the molecular architecture underlying the connectome by relating it to the neurotransmitter-receptor/transporter density maps. Resting-state functional magnetic resonance imaging was used to detect the functional connectome, and gait function was assessed via a 10 m-walking test. The functional connectome was first detected within drug-naive patients (N = 48) by using connectome-based predictive modeling following cross-validation and then successfully validated within drug-managed patients (N = 30). The results showed that the motor, subcortical, and visual networks played an important role in predicting gait function. The connectome generated from patients failed to predict the gait function of 33 normal controls (NCs) and had distinct connection patterns compared to NCs. The negative connections (connection negatively correlated with 10 m-walking-time) pattern of the PD connectome was associated with the density of the D2 receptor and VAChT transporter. These findings suggested that gait-associated functional alteration induced by PD pathology differed from that induced by aging degeneration. The brain dysfunction related to gait impairment was more commonly found in regions expressing more dopaminergic and cholinergic neurotransmitters, which may aid in developing targeted treatments.